Health Care · Services-Commercial Physical & Biological Research · Nasdaq · CIK 1287098 · FYE Dec 31 · Prices AT CLOSE 2026-08-19 (USD) Last $1.39 · Day +9.45% · Mkt cap $131M · 1Y −0.7% · Off 52W high −25.5% · Vol (1Y) 69.3% Price2023-08-21 → 2026-08-19 MXCT close: $3.77 on 2023-08-21 to $1.39 on 2026-08-19. Split-adj closes · 240 of 1,266 · price returnⓘ At a glance | Short interest1.2% of sh out | | Days to cover1.6d | | 13F net flow (QoQ)−2.04% | | Top-10 13F concentration64.9% | | Next report (est.)2026-11-12 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$31.1M | | Earnings (TTM)-$35.6M | | ROE−23.6% | | Net margin−135.1% | | Sales growth 3Y−9.3% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−10.3% | | 1Y−0.7% | | 3Y−63.1% | | 5Y−90.0% | | Since incept. (ann.)−72.5% |
Total return · from 2021-07-28ⓘ Risk | Ann. volatility (1Y)69.3% | | Ann. volatility (3Y)66.1% | | Sharpe (1Y)0.33 | | Sharpe (3Y)−0.17 | | Max drawdown (1Y)−63.1% | | Max drawdown (3Y)−87.4% | | Beta (3Y vs SPY)2.50 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| BlackRock, Inc. | 8.8M | $6M | 8.23% | −4.8% | | Capricorn Fund Managers Ltd | 8.2M | $6M | 7.67% | new | | Vitruvian Partners LLP | 5.0M | $4M | 4.72% | +0.0% | | VANGUARD CAPITAL MANAGEMENT LLC | 4.0M | $3M | 3.73% | new | | MORGAN STANLEY | 3.7M | $3M | 3.45% | −16.8% | | Mudita Advisors LLP | 3.4M | $2M | 3.15% | +0.0% | | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2.8M | $2M | 2.60% | +0.0% | | GEODE CAPITAL MANAGEMENT, LLC | 2.4M | $2M | 2.21% | −6.2% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-12 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-12 | −$0.08 | — | $7.3M | −14.5% | | 2026-03-31 | 2026-05-12 | −$0.04 | — | $9.7M | −7.1% | | 2025-12-31 | 2026-03-24 | — | — | $7.3M | −16.0% | | 2025-09-30 | 2025-11-12 | −$0.12 | — | $6.8M | −16.4% |
As-reported XBRL · next 2026-11-12 est.ⓘ Segment mixFY2025 (ended Dec 2025) Cell Engineering Technology 100% business · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
